Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

Background and purpose — The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was not recommended. Here, we detail the effect of pexida...

Full description

Bibliographic Details
Main Authors: Michiel Van De Sande, William D Tap, Heather L Gelhorn, Xin Ye, Rebecca M Speck, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J Wagner, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Qiang Wang, Dale Shuster, Hans Gelderblom, John H Healey
Format: Article
Language:English
Published: Medical Journals Sweden 2021-07-01
Series:Acta Orthopaedica
Online Access:http://dx.doi.org/10.1080/17453674.2021.1922161

Internet

http://dx.doi.org/10.1080/17453674.2021.1922161

Similar Items